NASDAQ: XNCR · Life Sciences · 4 alerts · CIK 1326732
Share price
$35.40Close, Nov 16
Market cap
$2.66B
Shares outstanding
75.04MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Xencor Inc filings on SEC EDGAR ↗
Xencor Sr. VP & CFO Bart Jan Cornelissen Sells $402K of Stock
Bart Jan Cornelissen, Sr. VP & CFO, sold 10,100 shares of Xencor Inc at $39.82 a share, worth $402K in total on Nov 11, 2026. Shares held after the trade: 65,798 (-13.3%).
Xencor Insider Richard J. Ranieri Sells $3.19M of Stock
Richard J. Ranieri sold 81,252 shares of Xencor Inc at $39.20 to $39.59 a share (average $39.25) in 2 transactions, worth $3.19M in total on Nov 10, 2026. Shares held after the trade: 18,514 (-37.6%).
Xencor reported financial results for the third quarter ended September 30, 2026, highlighting clinical progress for its lead bispecific antibody XmAb819 in renal cell carcinoma. The company ended the quarter with $412.4 million in cash and equivalents, providing a projected runway into 2028.
“Xencor’s lead CD3 T-cell engaging bispecific antibody, XmAb819, has demonstrated compelling clinical data in advanced clear cell renal cell carcinoma, and our plans for moving XmAb819 into earlier lines of treatment as a monotherapy and in combination with anti-PD(L)1 are underway, with evaluation of XmAb819 in additional ENPP3-positive tumor types also ongoing.”
Bassil Dahiyat, Ph.D., president and chief executive officer at Xencor
Xencor announced updated Phase 1 clinical trial results for XmAb819, an ENPP3 x CD3 bispecific T-cell engager, in patients with advanced clear cell renal cell carcinoma (ccRCC). The company also provided a cash runway update, expecting current resources to fund operations into 2029, and plans to start a potential registration-enabling study for XmAb819 in 2027.